The Vanguard Group, Inc. recently announced the acquisition of new stake in Immunogen, Inc. (NASDAQ:IMGN). The institutional investor has increased its shareholding in the Healthcare company by 17.35% to 23.92 million shares with purchase of 3.54 million shares. This fresh investment now brings its stake to 8.98% valued currently at $701.91 million. In addition, Janus Henderson Investors US LLC raised its holdings by 2.07 million to 16.98 million shares. And RA Capital Management LP has lifted its position by 471.78% or 10.99 million shares – to 13.32 million shares.
Currently, there are 267.66M common shares owned by the public and among those 261.25M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 82 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 63 of these insider trades were purchases, accounting for 4,356,007 shares. Insider sales of the common stock occurred on 19 occasions, with total insider shares sold totaling 4,269,035 shares.
The top 3 mutual fund holders in Immunogen, Inc. are Vanguard Total Stock Market ETF, Vanguard Small Cap Index Fund, and iShares Russell 2000 ETF. Vanguard Total Stock Market ETF owns 7.78 million shares of the company’s stock, all valued at over $228.38 million. The company bought an additional 14876.0 shares recently to bring their total holdings to about 2.92% of the shares outstanding. Vanguard Small Cap Index Fund bought 13308.0 shares to see its total holdings expand to 6.42 million shares valued at over $188.44 million and representing 2.41% of the shares outstanding. iShares Russell 2000 ETF bought 2859.0 shares to bring its total holdings to over 5.82 million shares at a value of $170.69 million. iShares Russell 2000 ETF now owns shares totaling to 2.18% of the shares outstanding.
However, the script later moved the day high at 29.91, up 1.32%. The company’s stock has a 5-day price change of 0.50% and 104.03% over the past three months. IMGN shares are trading 502.02% year to date (YTD), with the 12-month market performance up to 497.20% higher. It has a 12-month low price of $3.61 and touched a high of $29.96 over the same period. IMGN has an average intraday trading volume of 7.59 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 21.07%, 59.00%, and 107.73% respectively.
Institutional ownership of Immunogen, Inc. (NASDAQ: IMGN) shares accounts for 90.93% of the company’s 267.66M shares outstanding. Mutual fund holders own 39.63%, while other institutional holders and individual stakeholders account for 51.75% and 1.32% respectively.
It has a market capitalization of $7.99B and a beta (3y monthly) value of 1.16. The earnings-per-share (ttm) stands at -$0.30. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.00% over the week and 2.45% over the month.
Analysts forecast that Immunogen, Inc. (IMGN) will achieve an EPS of $0.13 for the current quarter, $0.04 for the next quarter and $0.37 for 2024. The lowest estimate earnings-per-share for the quarter is $0.07 while analysts give the company a high EPS estimate of $0.22. Comparatively, EPS for the current quarter was -$0.23 a year ago. Earnings per share for the fiscal year are expected to increase by 107.20%, and 474.72% over the next financial year.
Looking at the support for the IMGN, a number of firms have released research notes about the stock. Guggenheim stated their Neutral rating for the stock in a research note on December 01, 2023, with the firm’s price target at $25-$31.
